Research advances on target-mediated drug disposition(TMDD) models

doi:10.12092/j.issn.1009-2501.2018.05.001

Abstract

Abstract:

Since the formal concept of target-mediated drug disposition(TMDD) was proposed by Dr.Gerhard Levy in 1994, great progress has been achieved in this area.Thanks to the development of experimental techniques,more and more data are available for the mathematical modeling of TMDD.As the rise of biologics, the application of TMDD models becomes more and more prevalent in drug development. This review introduces the development of TMDD models and discusses the application of different variants.

Key words: target-mediated drug disposition, modeling and simulation, biologics

CLC Number:

R969

JI Shuangmin, ZHU Xiao, GAO Liucun, YANG Huan, GAO Chenyan. Research advances on target-mediated drug disposition(TMDD) models[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 481-487.

References

［1］Levy G.Pharmacologic target‐mediated drug disposition［J］.Clin Pharmacol Ther,1994,56(3):248-252.
［2］Dua P,Hawkins E,Van PDG.A tutorial on target-mediated drug disposition (TMDD) models［J］.CPT Pharmacometrics Syst Pharmacol,2015,4(6):324-337.
［3］Wang Y,Booth B,Rahman A,et al.Toward greater insights on pharmacokinetics and exposur-response relationships for therapeutic biologics in oncology drug development［J］.Clin Pharmacol Ther,2017,101(5):582.
［4］Mager DE,Jusko WJ.General pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］.J Pharmacokinet Pharmacodyn,2001,28(6):507-532.
［5］Cao Y, Jusko WJ. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model［J］. J Pharmacokinet Pharmacodyn, 2014, 41(6):571-580.
［6］Kagan L, Turner MR, Balu-Iyer SV, et al. Subcutaneous absorption of monoclonal antibodies: role of dose, site of injection, and injection volume on rituximab pharmacokinetics in rats［J］. Pharm Res, 2012, 29(2):490-499.
［7］Yan X, Chen Y, Krzyzanski W. Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor［J］. J Pharmacokinet Pharmacodyn, 2012, 39(5):543-560.
［8］Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target［J］. J Pharmacokinet Pharmacodyn, 2010, 37(4):323-346.
［9］Krippendorff BF, Kuester K, Kloft C, et al. Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis［J］. J Pharmacokinet Pharmacodyn, 2009, 36(3):239-260.
［10］Krippendorff BF, Oyarzún DA, Huisinga W. Predicting the F(ab)mediated effect of monoclonal antibodies in vivo by combining celllevel kinetic and pharmacokinetic modelling［J］. J Pharmacokinet Pharmacodyn, 2012, 39(2):125-139.
［11］Xiao JJ, Krzyzanski W, Wang YM, et al. Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys［J］. AAPS J , 2010, 12(4):646-657.
［12］Ruixo JJP, Ma P, Chow AT. The Utility of Modeling and Simulation Approaches to Evaluate Immunogenicity Effect on the Therapeutic Protein Pharmacokinetics［J］. AAPS J, 2013, 15(1):172-182.
［13］Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］. Pharm Res, 2005, 22(10):1589-1596.
［14］Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification［J］. J Pharmacokinet Pharmacodyn, 2012, 39(5):429-451.
［15］Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models［J］. J Pharmacokinet Pharmacodyn, 2010, 37(1):25-47.
［16］Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target-mediated drug disposition model and identifiability of model parameters［J］. J Pharmacokinet Pharmacodyn, 2008, 35(5):573-591.
［17］Ma P. Theoretical considerations of target-mediated drug disposition models: simplifications and approximations［J］. Pharm Res, 2012, 29(3):866-882.
［18］Wagner JG.A new generalized nonlinear pharmacokinetic model and its implications［M］. //Biopharmaceutics and relevant pharmacokinetics,drug Intelligence publications.Hamilton:Hamilton Press,1971:302-317.
［19］Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition［J］. Pharm Res, 2005, 22(10):1589-1596.
［20］Abraham AK, Krzyzanski W, Mager DE. Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition［J］. Aaps Journal, 2007, 9(2):E181-E189.
［21］Gibiansky L, Gibiansky E, Kakkar T, et al. Approximations of the target-mediated drug disposition model and identifiability of model parameters［J］. J Pharmacokinet Pharmacodyn, 2008, 35(5):573-591.
［22］Peletier LA, Gabrielsson J. Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification［J］. J Pharmacokinet Pharmacodyn, 2012, 39(5):429-451.
［23］季双敏, 朱校. 靶点介导的药物处置模型在单克隆抗体药物研发中应用的探讨［J］. 中国临床药理学与治疗学, 2018, 23(3):241-246.
［24］Betts AM, Clark TH, Yang J, et al. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf1 antibody for osteoporosis ［J］. J Pharmacol Exp Ther, 2010, 333(1):2-13.
［25］Luu KT,Bergqvist S,Chen E,et al. A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition［J］.J Pharmacol Exp Ther, 2012, 341(3): 702-708.

[1]	ZHANG Jinhua, LIU Maobai, CAI Mingzhi, ZHENG Yingli, LAO Haiyan, XIANG Qian, DU Liping, ZHU Zhu, DONG Jing, ZUO Xiaocong, LI Xingang, SHANG Dewei, CHEN Bing, YE Yanrong, WANG Yuzhu, GAO Jianjun, ZHANG Jian, CHEN Wansheng, XIE Haitang, JIAO Zheng. Model informed precision dosing of warfarin: China expert consensus report (2022 version) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1201-1212.
[2]	ZHANG Ningyuan, ZHENG Xijun, XU Ling, LIU Hongxia, ZHENG Qingshan. Disease progression model for Alzheimer's disease and its research progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 687-694.
[3]	JIAO Zheng, LI Xingang, SHANG Dewei, DONG Jing, ZUO Xiaocong, CHEN Bing, LIU Jianmin, PAN Yan, ZHOU Tianyan, ZHANG Jing, LIU Dongyang, LI Lujin, FANG Yi, MA Guangli, DING Junjie, ZHAO Wei, CHEN Rui, XIANG Xiaoqiang, WANG Yuzhu, GAO Jianjun, XIE Haitang, HU Pei, ZHENG Qingshan. Model informed precision dosing: China expert consensus report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1215-1228.
[4]	LI Jian, YANG Jinbo, WANG Yuzhu. Discussion on the format and content of new drug population pharmacokinetic study report [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
[5]	ZHANG Kaiting, CHEN Naihan. Development of therapeutic biologics in cancer treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 32-43.
[6]	ZHANG Huimin, LIU Aiming, ZHU Wenfeng, YU Lingzhi, CHEN Fangliang. Scientific decision process and regulation requirements based on the current guidelines of data extrapolation from adult to pediatric population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 49-56.
[7]	JI Shuangmin, ZHU Xiao. Application of target-mediated drug disposition (TMDD) models in the development of monoclonal antibody [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 241-246.
[8]	SHI Jun, Jeffrey S .Barrett. Pharmacometrics in pediatric drug development and rational dosage [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(1): 1-10.
[9]	HUANG Xiao-hui, XIE Hai-tang, SHI Jun, SONG Jian-guo, ZHENG Qing-shan. Advances in quantitative pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(6): 601-612.
[10]	HUANG Xiao-hui, SHI Jun, LI Jun, SONG Guo-qiang, XIE Hai-tang, ZHENG Qing-shan, SUN Ruiyuan. Pharmacokinetic-pharmacodynamic modeling and simulation:concepts and basic principles(2) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 334-341.
[11]	Bernd Meibohm. Pharmacokinetic and pharmacodynamic evaluation of biologics:challenges and pitfalls [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1089-1098.
[12]	HUANG Xiao-hui, SHI Jun, LI Jun, XIE Hai-tang, ZHENG Qing-shan, SUN Rui-yuan. Pharmacokinetic-pharmacodynamic modeling and simulation:concepts and basic principles(1) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 82-89.